Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELI-004
- Development stage
- Unknown
- Lead developer
- Elicio Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ELI-004 is an AMP-modified CpG oligodeoxynucleotide adjuvant developed using Elicio Therapeutics’ proprietary Amphiphile (AMP) technology. It is designed to enhance immune responses by targeting lymph nodes, where it stimulates antigen-presenting cells such as dendritic cells to activate T and B cell-mediated immunity. The AMP modification enables efficient delivery of the CpG oligonucleotide to lymph nodes via albumin binding, increasing its immunostimulatory potency. ELI-004 is used as an off-the-shelf subcutaneous adjuvant component in investigational cancer vaccines (notably in combination with mutant KRAS peptide antigens in the ELI-002 vaccine) and has also been studied as a vaccine adjuvant for infectious diseases such as COVID-19[1][2][3][4][5][7][9].
- Brand names
- Amph-CpG-7909Amph-CpG7909Amph-CpG 7909
- Other names
- Amph-CpG-7909Amph-CpG7909Amph-CpG 7909lipid-conjugated CpG-7909amphiphile CpG-7909amphiphilic CpG-7909
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on ELI-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELI-004.